# Teleflex: Phase 4 study in Thromboembolic Event, FDP (867 participants)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | Teleflex |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Safety And Field Evaluation of Plasma Lyophilized for Acute and Surgical Management Applications |
| NCT ID | NCT07840352 |
| Phase | Phase 4 |
| Status | not yet recruiting |
| Conditions | Thromboembolic Event; FDP |
| Intervention types | biological |
| Target enrollment | 867 |
| Posted | 2026-09-25 |
| Planned start | 2027-10 |
| Event | Newly registered study |
| Event date | 2026-09-25 |

## Why this score
- Industry sponsor (buys outsourced services).
- 867 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07840352). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.